MLTX

MoonLake Immunotherapeutics MLTX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-61.80M

Quarter to Jun 30

Free cash flow

$-55.56M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.43B total
BVF INC/IL
$311.54M0.0%
Deep Track Capital, LP
$136.27M+9.2%
T. Rowe Price Investment Management, Inc.
$83.34MNew
D. E. Shaw & Co., Inc.
$65.53M+40.8%
Cormorant Asset Management, LP
$62.41M-28.5%
Jupiter Topco LLC
$60.08M--
Logos Global Management LP
$52.08M+78.3%
Weiss Asset Management LP
$50.27M+51.1%
CITADEL ADVISORS LLC
$38.41M+49.0%
TWO SIGMA INVESTMENTS, LP
$33.40M+52.8%
MPM BioImpact LLC
$31.29M-11.3%
JPMORGAN CHASE & CO
$27.60M+27.4%
Vivo Capital, LLC
$27.26M+40.0%
Point72 Asset Management, L.P.
$22.56M-15.3%
BlackRock, Inc.
$21.32M+7.1%
PRICE T ROWE ASSOCIATES INC /MD/
$20.28M-19.6%
BALYASNY ASSET MANAGEMENT L.P.
$17.77M-14.3%
GREAT POINT PARTNERS LLC
$16.66M+71.2%
JANE STREET GROUP, LLC
$16.62M+88.1%
Candriam S.C.A.
$14.97M-5.9%
BANK OF AMERICA CORP /DE/
$14.64M+3.7%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$14.62M+970.4%
Trails Edge Capital Partners, LP
$14.60MNew
HRT FINANCIAL LP
$13.22M+33.2%
RENAISSANCE TECHNOLOGIES LLC
$12.52M+132.4%
See all 173 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/MLTX

Earnings Per Share

13fpro.ai/company/MLTX

Loading ratio trend…

MLTX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About MoonLake Immunotherapeutics (MLTX): stock profile, AI score and financials

MoonLake Immunotherapeutics (MLTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. MLTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), MoonLake Immunotherapeutics reports net income of $-61.8M, free cash flow of $-55.6M. Top institutional holders of MLTX by reported 13-F value include BVF, Deep Track Capital, T. Rowe Price Investment Management, based on the most recent SEC filings. MLTX trades on the Nasdaq exchange and files with the SEC under CIK 1821586. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MLTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MoonLake Immunotherapeutics directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1821586 →